CATALOG

ITALIAN WEBSITES

Domain and Website Information:

digitalin.it

Italiano




About site:


Domain name - digitalin.it


Site title - Work


Go to website - Work



Words count at digitalin.it:

work - 1
pagina - 1
costruzione - 1

See complete list



Site GEO location


Location Country - Italy



City/Town - Rome



Provider - Server Plan S.r.l.



digitalin.it GEO Location on Map



Site Logo



There is no Open Graph data at digitalin.it


Information for domain digitalin.it


IP address:

185.81.6.55


Domain name servers:


ns3.nicomed.it ns4.nicomed.it


All records:


☆ digitalin.it. 3600 IN TXT "v=spf1 +a +mx +ip4:185.81.6.55 ~all"
☆ digitalin.it. 14400 IN SOA ns3.nicomed.it. cpanel_notice.notifiche.serverplan.com. 2024060601 3600 1800 1209600 86400
☆ digitalin.it. 14400 IN NS ns4.nicomed.it.
☆ digitalin.it. 14400 IN NS ns3.nicomed.it.
☆ digitalin.it. 3600 IN A 185.81.6.55
☆ digitalin.it. 3600 IN MX 0 digitalin.it.



Whois server information for digitalin.it



Brief facts about digitalin:

Digoxin, sold under the brand name Lanoxin among others, is a medication used to treat various heart conditions. Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure. Digoxin is one of the oldest medications used in the field of cardiology. It works by increasing myocardial contractility, increasing stroke volume and blood pressure, reducing heart rate, and somewhat extending the time frame of the contraction. Digoxin is taken by mouth or by injection into a vein. Digoxin has a half life of approximately 36 hours given at average doses in patients with normal renal function. It is excreted mostly unchanged in the urine. Common side effects include breast enlargement with other side effects generally due to an excessive dose. These side effects may include loss of appetite, nausea, trouble seeing, confusion, and an irregular heartbeat. Greater care is required in older people and those with poor kidney function.

Inotropic agents

Cardenolides

Peripherally selective drugs

IARC Group 2B carcinogens

World Health Organization essential medicines

 

© DMS 2011-